Loading stockRelated stocks: Apparel & Other Finishd Prods of Fabrics & Similar Matl
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
We are a founder-led, direct-to-consumer healthcare apparel and lifestyle brand that seeks to celebrate, empower and serve current and future generations of healthcare professionals. We are committed to helping this growing, global community of professionals, whom we refer to as Awesome Humans, look, feel and perform at their best 24/7, 365 days a year.
$10.31
$0.01 (-0.10%)
EOD Jul 17, 2026
Operating margin is thin at 6.04%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 13.6% YoY with margins expanding 5.6pp. However, free cash flow softened 17%, worth monitoring whether this is timing or structural.
At 47x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 17% versus the prior year, cash generation momentum has weakened.
46.9x earnings, 51.2x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$666M
▲ +13.6% YoY
Net Income (TTM)
$41M
▲ +1159.2% YoY
Op. Margin
6.43%
▲ +5.6pp YoY
ROIC
6.66%
▲ +5.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$39M
▼ -17.4% YoY
Op. Cash Flow (TTM)
$49M
▼ -24.6% YoY
Net Debt
-$216M
Net Cash Position
Cash & Equiv.
$277M
5Y CAGR: +19.1%
5Y CAGR: +22.2%
Continue Research
At a P/E of 46.9 and a price-to-free-cash-flow of 51.2, Figs (FIGS) trades above a two-stage DCF intrinsic value of about $4.59 per share, so at $10.31 the stock looks overvalued (55.5% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Figs scores 37/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $4.59 per share for FIGS, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $3.44. At today's $10.31, that puts the stock about 55.5% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Figs scores 37 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 6.4% operating margin and a 6.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. FIGS currently trades above its estimated intrinsic value and scores 37/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.